Liquid Ventilation Improves Pulmonary Function And Cardiac Output In A Neonatal Swine Model Of Cardiopulmonary Bypass  by Cheifetz, Ira M. et al.
LIQUID VENTILATION IMPROVES PULMONARY FUNCTION AND CARDIAC OUTPUT IN A
NEONATAL SWINE MODEL OF CARDIOPULMONARY BYPASS
Ira M. Cheifetz, MDa
Michael L. Cannon, MDa
Damian M. Craig, MSb
George Quickb
Frank H. Kern, MDa
Peter K. Smith, MDb
Ross M. Ungerleider, MDb
Jon N. Meliones, MDa
Objective: Neonatal and infant cardiopulmonary bypass results in multior-
gan system dysfunction. Organ protective strategies have traditionally been
directed at the myocardium and brain while neglecting the sometimes
severe injury to the lungs. We hypothesized that liquid ventilation would
improve pulmonary function and cardiac output in neonates after cardio-
pulmonary bypass. Methods: Twenty neonatal swine were randomized to
receive cardiopulmonary bypass with or without liquid ventilation. In the
liquid-ventilated group, a single dose of perflubron was administered
before bypass. The control group was conventionally ventilated. Each
animal was placed on nonpulsatile, hypothermic bypass. Low-flow cardio-
pulmonary bypass was performed for 60 minutes. The flow rate was
returned to 125 ml/kg per minute, and after warming to 37° C, the animals
were removed from bypass. Hemodynamic and ventilatory data were
obtained after bypass to assess the effects of liquid ventilation. Results:
Without liquid ventilation, cardiopulmonary bypass resulted in a signifi-
cant decrease in cardiac output, oxygen delivery, and static pulmonary
compliance compared with prebypass values. Input pulmonary resistance
and characteristic impedance increased in these control animals. At 30, 60,
and 90 minutes after bypass, the animals receiving liquid ventilation
showed significantly increased cardiac output and static compliance and
significantly decreased input pulmonary resistance and characteristic
impedance compared with control animals not receiving liquid ventilation.
Conclusions: Liquid ventilation improved pulmonary function after neona-
tal cardiopulmonary bypass while increasing cardiac output. The morbidity
associated with cardiopulmonary bypass may be significantly reduced if the
adverse pulmonary sequelae of bypass can be diminished. Liquid ventila-
tion may become an important technique to protect the lungs from the
deleterious effects of cardiopulmonary bypass. (J Thorac Cardiovasc Surg
1998;115:528-35)
Neonates and children with congenital heart dis-ease who undergo cardiac operations may re-
quire cardiopulmonary bypass (CPB) during opera-
tive repair. Although exposure to this artificial
“system” is essential, several organ systems, includ-
ing the pulmonary system, are adversely affected by
CPB. This organ injury is magnified in neonates.1-3
The effects of CPB on neonatal pulmonary function
are complex. Alterations in pulmonary mechanics,
gas exchange, pulmonary artery pressure, surfactant
production, and pulmonary vascular resistance
(PVR) have been described in neonatal and pediat-
ric patients undergoing CPB.1, 4-8
Organ-protective strategies have traditionally
been targeted at myocardial and cerebral function.
With improvements in myocardial and cerebral pro-
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tection, operative techniques, and perioperative
care, early neonatal or infant repair is recom-
mended for most repairable congenital heart le-
sions.9, 10 Long-term results are encouraging; how-
ever, without a strategy for lung protection, the
pulmonary vasculature and parenchyma may suffer
severe injury after CPB, resulting in increased mor-
bidity and mortality, abnormal convalescence, and
prolonged ventilatory requirements. Many neonates
and infants have a prolonged intensive care unit
(ICU) admission because of this postoperative re-
spiratory insufficiency.1, 9 The main determination
of the length of stay of infants and children in the
ICU is the need for mechanical ventilation.
These pathophysiologic changes that occur in the
pulmonary system of neonates and pediatric pa-
tients after exposure to CPB also have an impact on
the cardiovascular system.4-6, 8, 11, 12 The effects of
respiratory insufficiency and mechanical ventilation
on cardiorespiratory interactions are well described
and are of increasing importance after CPB. The
overall cardiorespiratory adverse effects of CPB may
be significantly reduced if the initial lung injury can
be minimized.
The mechanism of the pulmonary vascular and
parenchymal injuries is multifactorial. CPB with
hypothermia may result in a variety of injuries,
including those related to oxygenation/reoxygen-
ation, hypoxemia, ischemia, and reperfusion. Expo-
sure of blood to nonendothelialized surfaces acti-
vates the immune system, including the complement
cascade. These injuries often result in decreased
pulmonary compliance, increased PVR, and, poten-
tially, decreased cardiac output. These abnormali-
ties of cardiorespiratory function may result in de-
creased oxygen delivery.
Liquid ventilation with perflubron (LiquiVent;
Alliance Pharmaceutical Corp., San Diego, Calif.)
may be beneficial in treating acute lung injury.13-21
The beneficial effects of liquid ventilation include its
antiinflammatory properties, alveolar distending
properties, surfactant-like function, and oxygen de-
livery capability. During CPB, the lungs are by-
passed and are usually not ventilated. Thus liquid
ventilation may provide an opportunity to access
and to protect the lungs during CPB. As a result,
administering perflubron to the lungs during CPB
might benefit the patient by modifying the adverse
pulmonary response to bypass.
At present, no clinical data are available on the
use of liquid ventilation in association with CPB for
cardiac operations. Thus the focus of our study was
to define the role of liquid ventilation on cardiac and
respiratory function after CPB. We hypothesized
that liquid ventilation initiated before CPB would
improve post-CPB pulmonary function and cardiac
output in a neonatal model of CPB. The beneficial
effects of liquid ventilation include exerting effects
similar to surfactant, functioning as a liquid positive
end-expiratory pressure to reduce atelectasis, pro-
viding antiinflammatory properties, and acting as an
oxygen carrier at the alveolar level. The physiologic
benefits of liquid ventilation would include im-
proved pulmonary compliance, decreased regional
hypoxic pulmonary vasoconstriction, improved car-
diac output, and increased oxygen delivery.
Materials and methods
Anesthesia and operation. The operative procedures
and animal care were in compliance with the guidelines
established by the National Institutes of Health and the
Institutional Animal Care and Use Committee of Duke
University Medical Center. Twenty neonatal swine (1
week old; 2.0 to 3.4 kg) were used in this study. Each
animal was premedicated with intramuscular aceproma-
zine maleate (INN: acepromazine) (1.1 mg/kg) and ket-
amine (22 mg/kg). Sodium thiopental (25 mg/kg) and
methylprednisolone sodium succinate (Solu-Medrol) (20
mg/kg) were administered after obtaining intravenous
access. The trachea was intubated with a cuffed endotra-
cheal tube compatible with perflubron, and the animal
was placed on an SV300 ventilator (Siemens-Elema;
Solno, Sweden) in the volume control mode. Initial ven-
tilatory settings included inspired oxygen fraction (Fio2),
1.0; delivered tidal volume (measured at the endotracheal
tube), 12 ml/kg; positive end expiratory pressure, 3 cm
H2O; and inspiratory time, 0.65 seconds. The respiratory
rate was adjusted to maintain an arterial carbon dioxide
tension (Paco2) between 35 and 45 mm Hg.
Anesthesia was maintained with a continuous infusion
of fentanyl. Intermittent boluses of pancuronium bromide
were administered for neuromuscular blockade. A femo-
ral artery catheter was placed for systemic blood pressure
monitoring and blood sampling. After a median sternot-
omy, the pericardium was incised, and a pericardial cradle
created. An ultrasonic transit-time flow probe (Transonic
Systems, Inc., Ithaca, N.Y.) was placed around the pul-
monary artery at the level of the right ventricular (RV)
outflow tract. Micromanometer pressure catheters (Millar
Instruments, Inc., Houston, Tex.) were placed in the right
ventricle and in the pulmonary artery at the level of the
ultrasonic flow probe.
CPB and liquid ventilation (Fig. 1). The animals ran-
domized to the control group were ventilated convention-
ally at the settings described. The animals randomized to
the intervention group received liquid ventilation before
CPB. Perflubron was administered to approximate the
functional residual capacity as determined by the presence
of perflubron in the endotracheal tube at a positive
end-expiratory pressure of 0 cm H2O. The perflubron
dose was limited to a maximum of 20 ml/kg. The per-
The Journal of Thoracic and
Cardiovascular Surgery
Volume 115, Number 3
Cheifetz et al. 5 2 9
flubron was administered over 15 to 20 minutes by use of
standard technique through the side-port of an adapter on
the endotracheal tube.13, 15-19 Perflubron administration
was completed before cannulation for CPB. No further
doses of perflubron were administered.
After heparinization (300 units/kg), each piglet was
placed on conventional, nonpulsatile CPB. Cannulation
was accomplished by placing an 8F infant arterial cannula
in the ascending aorta and a single 22F venous cannula in
the right atrium. Each animal was cooled over 20 minutes
to a nasopharyngeal temperature of 18° C. After cooling,
the flow was adjusted to 35 ml/kg per minute for 60
minutes to maintain a mean arterial pressure less than or
equal to 45 mm Hg. During this period of low-flow CPB,
the ventilator was set to deliver a constant positive airway
pressure of 5 cm H2O with the Fio2 decreased to 0.21.
After the 60-minute period of low-flow CPB, the ventila-
tor settings were adjusted to Fio2, 1.0; delivered tidal
volume, 12 ml/kg; positive end-expiratory pressure, 5 cm
H2O; and inspiratory time, 0.65 seconds. After a 20- to
30-minute period of rewarming, the animals were re-
moved from CPB. All animals in both groups were started
on a dopamine infusion at 10 mg/kg per minute at the time
of separation from CPB.
Data collection. Data were collected for the control
group at baseline before bypass. Baseline data for the
liquid ventilation group were obtained at baseline before
both CPB and the administration of perflubron. Post-CPB
data were collected for both groups at 30, 60, and 90
minutes after separation from CPB.
Measurements. The determination of the pulmonary
parenchymal injury consisted of evaluating respiratory
mechanics and gas exchange. All respiratory mechanics
measurements were obtained using a pneumotachometer
and a stand-alone respiratory mechanics monitor (Ven-
trak, Novametrix Medical Systems; Wallingford, Conn.).
Measurements included peak inspiratory pressure, pla-
teau pressure, mean airway pressure, dynamic compli-
ance, and total airways resistance. Static compliance was
calculated as delivered tidal volume divided by the differ-
ence between the plateau pressure and the positive end-
expiratory pressure.
Cardiac output was determined by the ultrasonic pul-
monary artery flow probe. Oxygen delivery was deter-
mined by the standard calculation of cardiac output 3
(1.34 3 hemoglobin 3 oxygen saturation 1 0.003 3 Pao2).
In addition to the standard measures of pulmonary
artery pressure and pulmonary blood flow, the pulmonary
vascular injury was assessed by pulmonary input resistance
and pulmonary characteristic impedance. To calculate the
impedance spectrum, the data sets were individually sep-
arated into cardiac cycles and waveform averaged.22 Char-
acteristic impedance, which is derived from the imped-
ance spectrum, describes the physical properties of the
pulmonary vascular bed and is inversely related to its
compliance and cross-sectional area.22-24 Characteristic
impedance describes the resistance of the larger, proximal
pulmonary vessels. In contrast, pulmonary input resis-
tance (mean pulmonary artery pressure/mean pulmonary
blood flow) evaluates the entire pulmonary vasculature
(large proximal vessels and small distal vessels).22-24 The
measurements of both pulmonary characteristic imped-
ance and input resistance allow for a comprehensive
evaluation of the reactivity of the pulmonary vasculature.
Statistical analysis. The pre-CPB baseline data for
each group were compared with the data 30 minutes after
CPB by paired t tests. The data at baseline were compared
between the two groups by unpaired t tests to ensure
appropriate randomization. The post-CPB data (30, 60,
and 90 minutes) were compared between the two groups
using a linear regression model of analysis of variance with
repeated measures. All data are indicated as mean 6
standard error of the mean.
Results
At baseline (pre-CPB), the control group (n 5 11)
and the intervention group (n 5 9) were similar in
terms of hemodynamics, gas exchange, pulmonary
reactivity, pulmonary compliance, cardiac output,
and oxygen delivery (Tables I to III). The average
weight of the control animals was 2.70 6 0.15 kg
compared with 2.69 6 0.13 kg for the animals
receiving liquid ventilation.
The pre-CPB data for both the control and the
liquid ventilation groups were compared with the
data 30 minutes after separation from CPB to
characterize the effects of CPB on the pulmonary
system and to assess the modification of these effects
by liquid ventilation (Tables I and II). Without
liquid ventilation, CPB resulted in a significant
decrease in cardiac output (229 6 29 vs 140 6 18
ml/min, p 5 0.02) and oxygen delivery (3.98 6 0.49
vs 2.44 6 0.30 L/min, p 5 0.02) while increasing
input pulmonary resistance (4434 6 527 vs 22,522 6
4713 dynes z sec z cm5, p 5 0.004) and characteristic
impedance (794 6 78 vs 1339 6 219
dynes z sec z cm5, p 5 0.05). Static compliance de-
creased in the control group with CPB (1.23 6 0.11
vs 0.84 1 0.06 ml/cm H2O per kilogram, p 5 0.004).
Fig. 1. Diagrammatic representation of the animal pro-
tocol. CPB, Cardiopulmonary bypass; CTL, control ani-
mals; LV, liquid ventilation.
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In animals receiving liquid ventilation, CPB resulted
in a significant increase in input pulmonary resis-
tance (4294 6 537 vs 10,850 6 805 dynes z sec z cm5,
p 5 0.001) and decrease in static compliance (1.36 6
0.15 vs 1.08 6 0.11 ml/cm H2O per kilogram, p 5
0.001); however, no significant changes were ob-
served in cardiac output (223 6 22 vs 215 6 18
ml/min), oxygen delivery (3.90 6 0.39 vs 3.66 6 0.28
L/min), or characteristic impedance (801 6 113 vs
913 6 59 dynes z sec z cm5).
The post-CPB data (30, 60, and 90 minutes) were
compared between the two groups using a linear
regression model of analysis of variance with re-
peated measures at 30, 60, and 90 minutes after CPB
to characterize the degree of lung protection offered
by the liquid ventilation. At 30 minutes after sepa-
ration from CPB, animals receiving liquid ventila-
tion had increased cardiac output (54%), increased
oxygen delivery (50%), decreased input pulmonary
resistance (52%), decreased characteristic imped-
ance (32%), and improved static compliance (26%)
compared with control animals not receiving liquid
ventilation. These statistically and clinically signifi-
cant differences were maintained throughout the
90-minute data acquisition period, although to a
lesser degree (Tables I and II).
At baseline and at 30, 60, and 90 minutes after
separation from CPB, no statistically or clinically
significant differences were observed in pH, Paco2,
systemic pressures, mean airway pressure, or total
airways resistance (Tables II and III). Oxygenation
was higher after CPB in the control group but not to
a clinically significant degree. At baseline and at 30
minutes after CPB, peak inspiratory pressure and
dynamic compliance were similar. However, at 60 and
90 minutes after CPB, peak inspiratory pressure
trended lower and dynamic compliance trended higher
in the group treated with liquid ventilation (Table II).
Discussion
Neonatal and pediatric patients with respiratory
dysfunction resulting from CPB have a significantly
increased morbidity and mortality.1 The pulmonary
injury that occurs in these patients and the effects of
this injury on cardiac function are not well under-
stood. Improving lung function and lessening the
sequelae associated with respiratory insufficiency in
the immediate post-CPB period is essential in re-










pre-CPB CTL 4434 6 527 794 6 78 229 6 29 3.98 6 0.49
LV 4294 6 537 801 6 113 223 6 22 3.90 6 0.39
30 min CTL 22,522 6 4713* 1339 6 219* 140 6 18* 2.44 6 0.30*
LV 10,850 6 805†‡ 913 6 59† 215 6 18† 3.66 6 0.28†‡
60 min CTL 17,865 6 2517* 1228 6 113* 153 6 19* 2.65 6 0.32*
LV 12,045 6 1896†‡ 744 6 52† 190 6 21†‡ 3.23 6 0.35‡
90 min CTL 18,738 6 2790* 1114 6 125* 146 6 15* 2.55 6 0.27*
LV 13,793 6 1852†‡ 922 6 136† 170 6 12†‡ 2.92 6 0.21‡
CTL, Control group; LV, liquid ventilation group; Rin, input pulmonary vascular resistance; Zo, characteristic impedance; CO, cardiac output; DO2, oxygen
delivery.
*p , 0.05 vs pre-CPB CTL; †p , 0.05 vs CTL; ‡p , 0.05 vs pre-CPB LV.














pre-CPB CTL 7.42 6 0.01 42 6 1 457 6 26 16.8 6 0.8 4.7 6 0.2 1.23 6 0.11 1.33 6 0.16 113 6 4
LV 7.44 6 0.01 38 6 1 472 6 22 15.6 6 0.9 4.6 6 0.2 1.36 6 0.15 1.32 6 0.12 111 6 5
30 min CTL 7.39 6 0.02 44 6 2 456 6 41 23.5 6 1.1 7.6 6 0.2 0.84 6 0.06* 0.95 6 0.08 138 6 5
LV 7.37 6 0.02 44 6 1 322 6 37†‡ 22.0 6 1.0 7.9 6 0.2 1.08 6 0.11†‡ 0.95 6 0.09 133 6 4
60 min CTL 7.36 6 0.02 39 6 4 439 6 41 24.3 6 1.2 7.8 6 0.2 0.81 6 0.07* 0.89 6 0.07 141 6 5
LV 7.38 6 0.01 44 6 2 317 6 31†‡ 22.0 6 1.0 8.0 6 0.2 1.10 6 0.11†‡ 0.95 6 0.08 134 6 5
90 min CTL 7.39 6 0.01 42 6 1 448 6 32 25.1 6 1.1 7.9 6 0.2 0.75 6 0.06* 0.84 6 0.06 147 6 7
LV 7.40 6 0.02 42 6 1 359 6 37†‡ 22.9 6 1.0 8.1 6 0.2 1.02 6 0.11†‡ 0.90 6 0.08 137 6 5
CTL, control group; LV, liquid ventilation group; PIP, peak inspiratory pressure; MAP, mean airway pressure; Cstat, static compliance; Cdyn, dynamic
compliance; TAR, total airways resistance. Mean 6 SEM.
*p , 0.05 vs pre-CPB CTL; †p , 0.05 vs CTL; ‡p , 0.05 vs pre-CPB LV.
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ducing morbidity and mortality. This is especially
important in neonates because the lung injury that
occurs in these patients is particularly severe.1, 25
Liquid ventilation appears to be quite promising in
improving lung function during acute lung dis-
ease.13-21 If liquid ventilation improves pulmonary
parenchymal mechanics, pulmonary vascular me-
chanics, and cardiac output after CPB, then overall
cardiorespiratory performance will improve.
After operation for congenital heart disease, pul-
monary insufficiency can significantly alter cardio-
vascular performance. These changes may be signif-
icant and cause abnormal ventricular function in
neonates and young children because the required
repair can disrupt the normal myocardial architec-
ture, resulting in direct myocardial injury, whereas
CPB contributes to myocardial edema and changes
in loading conditions.9, 10 In the postoperative pe-
riod, the right ventricle may be unable to increase its
work load when presented with increased RV after-
load resulting from pulmonary vasoconstriction. In
addition, a deterioration in respiratory parenchymal
function after bypass may result in the need for
increased airway pressures. This increased ventila-
tory support may further compromise RV function
by limiting RV preload and/or further increasing
RV afterload. Decreased RV output would de-
crease left ventricular preload and therefore de-
crease systemic cardiac output.
Mechanisms of CPB-induced lung injury. The
pathophysiology of the CPB-induced pulmonary in-
jury is not well understood. This pulmonary injury is
most probably multifactorial with causes including
oxygenation/reoxygenation, hypoxemia, ischemia,
reperfusion, and surfactant dysfunction.5, 11, 12, 26-29
A systemic inflammatory response occurs during CPB
as blood contacts nonphysiologic surfaces.5, 11, 26-28
This inflammatory response is characterized by com-
plement activation, leukocyte degranulation, neu-
trophil activation, increased capillary permeability,
and membrane injury.5, 11, 26-28 Complement activa-
tion may compromise lung function by altering
airways resistance and pulmonary compliance.5 Sur-
factant function has been shown to decrease with
CPB in children.29 Surfactant dysfunction correlates
with increased atelectasis and decreased pulmonary
compliance. Hypothermia and nonpulsatile perfu-
sion may induce pulmonary injury by altering the
patterns of pulmonary blood flow.4, 5, 11
Sequelae of the CPB-induced pulmonary injury.
Management of the pulmonary insufficiency during
the postoperative period requires an understanding
of the physiologic consequences of CPB. Capillary
leak with alveolar edema resulting from pulmonary
endothelial cell injury reduces pulmonary compli-
ance and functional residual capacity and increases
the alveolar-arterial oxygen gradient7, 8, 30 In addi-
tion, atelectasis causes ventilation-perfusion mis-
match, the development of intrapulmonary shunt-
ing, and pulmonary vasoconstriction that manifests
clinically as increased PVR, increased pulmonary
artery pressure, decreased arterial saturation, and
reduced arterial oxygen content.2, 3, 7, 31 Therapy for
pediatric patients with pulmonary insufficiency is
directed at reducing and/or preventing endothelial
cell injury and alveolar collapse.
Our study data confirm these bypass-associated
vascular and parenchymal pulmonary injuries. The
increases in input pulmonary resistance and character-
istic impedance were associated with a decrease in
cardiac output and oxygen delivery. Decreased static
compliance supports the presence of the parenchymal
injury.
Liquid ventilation. Liquid ventilation has the po-
tential to be beneficial in both clinical and animal
evaluations of acute lung injury.13, 21 In liquid ven-
tilation perflubron is instilled into the injured lungs
at a volume that approximates the functional resid-
ual capacity of the lungs.13 The patient is then
conventionally ventilated. Perflubron may have an-
tiinflammatory properties and may eliminate the
air-fluid interface, decreasing surface tension and
providing a surfactant-like effect. In addition, the
presence of liquid in the alveoli maintains alveolar
patency by exerting a continuous alveolar distending
pressure during the expiratory phase (“liquid posi-
tive end-expiratory pressure”). These effects of per-
flubron would decrease alveolar atelectasis and









pre-CPB CTL 81 6 5 60 6 4 48 6 4
LV 74 6 5 55 6 5 44 6 5
30 min CTL 74 6 5 53 6 4 39 6 3
LV 83 6 6 57 6 5 41 6 4
60 min CTL 66 6 6* 48 6 4* 37 6 3*
LV 65 6 3† 44 6 2† 32 6 3†
90 min CTL 62 6 5* 47 6 3* 36 6 4*
LV 67 6 4† 46 6 2† 33 6 3†
CTL, Control group; LV, liquid ventilation group; SBP, systolic systemic
blood pressure; MBP, mean systemic blood pressure; DPB, diastolic
systemic blood pressure. Mean 6 SEM.
*p , 0.05 vs pre-CPB CTL; †p , 0.05 vs pre-CPB LV.
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lungs.32 Thus liquid ventilation should improve pul-
monary compliance while reducing PVR and im-
proving cardiac output and oxygen delivery.13-21
In our study, the use of liquid ventilation im-
proved post-bypass pulmonary function. Therefore
the degree of lung injury seen after CPB may have
been less in the animals receiving perflubron ther-
apy than in the control animals. After CPB, the
animals receiving liquid ventilation did have a mod-
est increase in input pulmonary resistance and de-
crease in static compliance. However, a significant
change in cardiac output, oxygen delivery, or char-
acteristic impedance was not observed. When com-
paring the liquid ventilation group with the control
group, a significant reduction in pulmonary paren-
chymal and vascular injury was seen at 30, 60, and 90
minutes after CPB. These data suggest that liquid
ventilation may have helped to protect the lungs from
the deleterious effects of CPB in this neonatal model.
An improvement in static compliance implies the
ability to deliver the same tidal volume at a lower
airway pressure. Postoperatively, this decrease in
airway pressure should correlate with a decreased
risk for barotrauma, potentially a decreased length
of mechanical ventilation, and an improvement in
cardiorespiratory interactions.
Although the exact mechanisms of the pulmonary
vascular protection offered by liquid ventilation re-
main uncertain, the relationship of various physio-
logic changes can be hypothesized. Some combina-
tion of the beneficial effects of liquid ventilation,
including its antiinflammatory properties, alveolar
distending properties, surfactant-like function, and
oxygen delivery capability, resulted in a decrease in
pulmonary reactivity. This improvement was dem-
onstrated by a decrease in both input resistance and
characteristic impedance. Presumably, this decrease
in the afterload to the right ventricle resulted in
improved RV function and, subsequently, increased
global cardiac output. The increased cardiac output
resulted in a clinically significant improvement in
oxygen delivery.
Potential adverse effects. Liquid ventilation is not
without theoretical risks.13-19, 33 The presence of
perflubron in the alveolar space may result in ad-
verse effects on cardiorespiratory function. As a
liquid, perflubron is an excellent carrier of oxygen;
however, it is not as efficient as gas in transporting
oxygen. When perflubron is placed in the alveoli, the
maximum alveolar-arterial oxygen tension obtain-
able is 350 to 400 mm Hg versus 713 mm Hg for a
gas at standard temperature and pressure.32 This
results in an obligatory alveolar-arterial oxygen gra-
dient when perflubron is instilled into normal lungs.
Thus in normal lungs this has the potential to
decrease the arterial oxygen content and lead to
hypoxemia. However, in the early operative period,
ventilating a patient with normal lung function and
without a right-to-left shunt with an Fio2 of 1.0
would result in a arterial oxygen tension of 300 to
400 mm Hg, and this should not pose any risk to the
patient. If the patient does have underlying lung
disease, previous animal studies have demonstrated
that when lung injury is present perflubron increases
the systemic arterial oxygen content compared with
conventional ventilation at similar settings.13-19, 33 In
situations in which the concern over possible hyp-
oxia exists, the perflubron may be administered
immediately after cannulation for bypass.
Theoretically, perflubron may alter cardiorespira-
tory performance by altering intrathoracic pressure.
When perflubron is instilled into the lungs, the
weight of the liquid (1.92 gm/ml) may increase
intrathoracic pressure.32 This increase in intratho-
racic pressure may limit preload and decrease car-
diac output by decreasing RV filling. Our data do
not support this theoretical risk. In addition, per-
flubron has the potential to expand the alveolus and
compress the pulmonary vasculature. Potentially,
this may lead to an increase in pulmonary artery
resistance and a worsening of RV function if RV
afterload is significantly increased. The results from
this study indicate that PVR and cardiac output are,
in fact, improved with perflubron therapy. There-
fore the theoretical concern that perflubron may
adversely affect cardiorespiratory performance does
not seem valid under the conditions of this study.
Limitations of the study. Perflubron has been
shown to evaporate over time.13, 32 Therefore the
initial dose of perflubron may be inadequate to
maintain the improvement in lung function hypoth-
esized. Supplemental doses of perflubron may be
needed; however, the effects of maintaining a con-
stant volume of perflubron in the lungs by providing
additional dosing was not the intent of this study.
Additionally, this study was an acute study and did
not answer the question of the effects of liquid
ventilation on the length of mechanical ventilation.
By administering the perflubron before CPB, it
cannot be determined from our data whether liquid
ventilation prevented the pulmonary lung injury or
treated the lung injury as it was occurring. In either
case, the net result was improved pulmonary func-
tion with liquid ventilation after bypass. Future
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experiments with perflubron dosing before and after
bypass can be performed to determine whether
liquid ventilation prevents or treats the lung injury
associated with CPB and to identify the exact mech-
anisms involved.
Our evaluation of liquid ventilation immediately
after bypass represents a time period of increased
vulnerability for the neonate because the cardiore-
spiratory abnormalities that develop are at their
peak. Data obtained during this “high-risk” phase
can be extrapolated to clinical practice and are
essential to design future clinical and laboratory
investigations. The long-term effects of liquid venti-
lation may be a subject of future research.
We have demonstrated that the lung protection
strategy of liquid ventilation improved pulmonary
vascular and parenchymal function and cardiac out-
put in a neonatal model of CPB. The morbidity
associated with CPB may be significantly reduced if
the adverse pulmonary sequelae of CPB can be
diminished. Liquid ventilation may become an im-
portant technique for protecting the lungs from the
deleterious effects of CPB.
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Discussion
Dr. John E. Mayer (Boston, Mass.). In reviewing the
manuscript, I must say that several questions occurred to
me and I have several comments. As I am sure you know,
the relationship between pulmonary blood flow and PVR
and pulmonary impedance is complicated, and it is clear
that one and the other can clearly interrelate. It can be
hard sometimes to separate cause from effect. In the
discussion of your manuscript you hypothesize that it is
the lower impedance to pulmonary blood flow that re-
sulted in increased RV output and cardiac output. So my
first question is, do you have data on RV filling pressures,
RV ejection fraction, RV end-diastolic or end-systolic
volumes to support this hypothesis that it is the lower
resistance or impedance that resulted in improved RV
function?
The second question centers around the lung mechanics
that you observed in the treated group versus the un-
treated group. Because the static compliance was better in
the treated animals but the Pco2 was the same in each of
the two groups, it seems that the ventilatory management
would have to have been altered to keep those same
parameters. I wonder whether you could comment on how
you think the compliance changes affected the pulmonary
hemodynamic parameters that you measured. Along those
same lines, clearly some relationship exists between PVR
parameters and lung volumes, and traditionally it has been
taught that lowest PVR occurs at functional residual
capacity. So I wonder whether you might tell us if you
measured any lung volume parameters, such as functional
residual capacity, in your treated and untreated animals
and if you have any idea where you were operating in the
range between residual volume and total lung capacity.
The last question that I have relates to the hypothesis
that somehow pulmonary vascular endothelial function is
preserved. I wonder whether you have done any studies to
demonstrate any differences in pulmonary endothelial
function or whether you have any evidence that the
perflubron is actually absorbed intravascularly and there-
fore would be a way that pulmonary vascular endothelial
protection might be present.
Dr. Cheifetz. Thank you, Dr. Mayer, for reviewing the
manuscript and providing some very thoughtful questions.
In terms of the RV filling pressure, we have data that
demonstrate that RV end-diastolic pressures were main-
tained constant throughout the protocol. This was our
best approximation of preload. In addition, the volume
management of the animals was the same for both groups.
So to the best that we can determine from our data, the
preload was identical between the two groups. Therefore
our assumption is that the improvement in cardiac output
is a result of the decrease in afterload in the liquid
ventilation group compared with the control group.
Discussing lung mechanics in more detail, Pco2 was
maintained identically between the two groups by main-
taining the same tidal volume between the control group
and the liquid ventilation group. The improvement in
static compliance occurs because the plateau pressure is
actually lower in the liquid-treated animals for the same
tidal volume. So, we see an improvement in lung mechan-
ics while maintaining the same tidal volume and, there-
fore, the same Pco2.
In terms of the relationship between the plateau pres-
sure, which is decreased in the liquid-treated animals
compared with the control animals, and PVR, we have not
done any specific correlations between these values. How-
ever, the changes in plateau pressures are small and probably
do not relate to a large degree to the changes in PVR.
Discussing lung volumes in more detail, in the liquid-
treated animals the perflubron was dosed to functional
residual capacity using standard technique that has been
performed in both clinical and in animal studies. Our best
assumption on the basis of prior studies, is that the liquid
animals were maintained at functional residual capacity.
In the control animals we did not perform any determina-
tions of lung volume. I do not know whether these animals
were functioning at or below functional residual capacity.
However, for the purposes of this study we were attempting
to determine the difference between liquid and control
animals knowing that the liquid-treated animals would prob-
ably be functioning at slightly higher lung volumes.
Last, in terms of the endothelial function, in this first
pilot study we did not specifically test any markers of
endothelial cell injury. However, this topic is a central
component to our follow-up studies. We are attempting to
determine how much of an antiinflammatory effect the
perflubron does have in this animal model and how much
improvement we can see, simply because perflubron has
some antiinflammatory properties. There is minimal ab-
sorption of perflubron intravascularly and that exact
amount is still uncertain in this animal model.
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